Niacin

Niacin

SCHEMBL5485587

O=C(O)c1cccnc1.c1cc[nH]c1

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.78
APP P05067 1/20 0.78
GAA P10253 1/20 0.78
HCAR3 P49019 1/20 0.78
HCAR2 Q8TDS4 1/20 0.78
PLOD2 O00469 2/20 0.56
F7 P08709 1/20 0.53
F3 P13726 1/20 0.53
SARM1 Q6SZW1 1/20 0.53
SIRT2 Q8IXJ6 1/20 0.53
SIRT6 Q8N6T7 1/20 0.53
SIRT1 Q96EB6 1/20 0.53
SIRT3 Q9NTG7 1/20 0.53
SIRT5 Q9NXA8 1/20 0.53
SIRT4 Q9Y6E7 1/20 0.53
KMO O15229 1/20 0.53
MKNK1 Q9BUB5 1/20 0.51
MKNK2 Q9HBH9 1/20 0.51
THRB P10828 1/20 0.50
HDAC1 Q13547 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niacin SCHEMBL28284407 0.98 ALDH1A1 (0.75) ALDH1A1APPGAAHCAR3HCAR2
Niacin SCHEMBL150011 0.88 ALDH1A1 (1.00) ALDH1A1APPGAAHCAR3HCAR2
Niacin SCHEMBL29396199 0.88 ALDH1A1 (1.00) ALDH1A1APPGAAHCAR3HCAR2
Niacin SCHEMBL29349574 0.88
Niacin SCHEMBL1433 0.88
Niacin SCHEMBL28292236 0.88 ALDH1A1 (1.00) ALDH1A1APPGAAHCAR3HCAR2
Niacin SCHEMBL3081560 0.88 ALDH1A1 (1.00) ALDH1A1APPGAAHCAR3HCAR2
Niacin SCHEMBL30844065 0.88
Niacin SCHEMBL23780926 0.86 ALDH1A1 (0.95) ALDH1A1APPGAAHCAR3HCAR2
Niacin SCHEMBL23780929 0.86 ALDH1A1 (0.95) ALDH1A1APPGAAHCAR3HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103974948-B Substituted benzyl indazoles as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases 拜耳医药股份有限公司 2017-07-28 CN claimed
CN-105218546-B Synthesis process of 1H-pyrrolo[2,3-B] pyridine-3-carboxylic methyl ether 上海泰坦科技股份有限公司 2017-05-17 CN claimed
CN-104583197-B New bicyclicpyridine derivatives 霍夫曼-拉罗奇有限公司 2017-05-17 CN claimed
CN-100571704-C Fixed dosage antitubercular agent compound pharmaceutical and preparation method thereof UNIV SHENYANG PHARMACEUTICAL (CN) 2009-12-23 CN claimed
CN-1611218-A Fixed dose compound preparation of antitubercular drug and its preparing method UNIV SHENYANG PHARMACEUTICAL (CN) 2005-05-04 CN claimed
CN-107074800-B substituted bicyclic heteroaryl compounds as RXR agonists 康内克斯生命科学私人有限公司 2019-11-12 CN disclosed
CN-110372699-A A kind of synthetic method of the excessive state impurity of Eliquis 新乡双鹭药业有限公司 2019-10-25 CN disclosed
CN-110225758-A The alimentation composition of the dietary management of eilema is provided MJN 美国控股有限责任公司 2019-09-10 CN disclosed
CN-105473554-B Condensed piperidine amide as ion channel modulators 沃泰克斯药物股份有限公司 2019-08-13 CN disclosed
CN-110036009-A Substituted pyrrolidines and their use in the treatment of cystic fibrosis 艾伯维公司 2019-07-19 CN disclosed
CN-110035993-A SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS 艾伯维公司 2019-07-19 CN disclosed
CN-110022875-A Therapeutic inhibiting compound 莱福斯希医药公司 2019-07-16 CN disclosed
CN-106659228-A Nutritional compositions relating to subjects with cow's milk protein allergy MJN 美国控股有限责任公司 2017-05-10 CN disclosed
CN-106588916-A N-(phenoxyethyl) imidazo [1,2-a] pyridine-3-amide compound and preparation method thereof 浙江司太立制药股份有限公司 2017-04-26 CN disclosed
CN-104981470-B Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use 拜耳制药股份公司 2017-04-19 CN disclosed
CN-104114553-B Substituted pyrazolo [1,5 a] pyridine as tropomyosin receptor kinase (Trk) inhibitor 雷迪博士实验室有限公司 2017-03-01 CN disclosed
CN-100571704-C Fixed dosage antitubercular agent compound pharmaceutical and preparation method thereof UNIV SHENYANG PHARMACEUTICAL (CN) 2009-12-23 CN disclosed
CN-100515419-C Substituted benzazoles and its application as inhibitors of Raf kinase CHIRON CORP (US) 2009-07-22 CN disclosed
US-20070299091-A1 Azaindole Carboxamides GMEINER PETER 2007-12-27 US disclosed
CN-1611218-A Fixed dose compound preparation of antitubercular drug and its preparing method UNIV SHENYANG PHARMACEUTICAL (CN) 2005-05-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299091-A1 Azaindole Carboxamides TPH1, TPH2, HTR1A ALDH1A1 505/4885APP 3220/4885GAA 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.